Concourse Financial Group Securities, Inc. Xortx Therapeutics Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 30, 2023
BUY
$0.54 - $0.8 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$0.54 - $0.8 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$0.45 - $0.81 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$0.45 - $0.87 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.73 - $10.71 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.94 - $10.98 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$1.16 - $1.97 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$1.16 - $2.15 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$1.8 - $5.84 $0 - $0
0 New
0 $0

About XORTX Therapeutics Inc.

XRTX Quotes by TradingView
  • Ticker XRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,389,700
  • Market Cap $15.8M
  • Description
  • XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic ki...
More about XRTX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email